First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors
Copyright © 2023 Elsevier Inc. All rights reserved..
OBJECTIVE: UGN-101 has been approved for the chemoablation of low-grade upper tract urothelial cancer (UTUC) involving the renal pelvis and calyces. Herein is the first reported cohort of patients with ureteral tumors treated with UGN-101.
PATIENTS AND METHODS: We performed a retrospective review of patients treated with UGN-101 for UTUC at 15 high-volume academic and community centers focusing on outcomes of patients treated for ureteral disease. Patients received UGN-101 with either adjuvant or chemo-ablative intent. Response rates are reported for patients receiving chemo-ablative intent. Adverse outcomes were characterized with a focus on the rate of ureteral stenosis.
RESULTS: In a cohort of 132 patients and 136 renal units, 47 cases had tumor involvement of the ureter, with 12 cases of ureteral tumor only (8.8%) and 35 cases of ureteral plus renal pelvic tumors (25.7%). Of the 23 patients with ureteral involvement who received UGN-101 induction with chemo-ablative intent, the complete response was 47.8%, which did not differ significantly from outcomes in patients without ureteral involvement. Fourteen patients (37.8%) with ureteral tumors had significant ureteral stenosis at first post-treatment evaluation, however, when excluding those with pre-existing hydronephrosis or ureteral stenosis, only 5.4% of patients developed new clinically significant stenosis.
CONCLUSIONS: UGN-101 appears to be safe and may have similar efficacy in treating low-grade urothelial carcinoma of the ureter as compared to renal pelvic tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Urologic oncology - 42(2024), 1 vom: 01. Jan., Seite 20.e17-20.e23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jacob, Joseph M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemoablation |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2023.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360177565 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360177565 | ||
| 003 | DE-627 | ||
| 005 | 20240411232059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2023.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM360177565 | ||
| 035 | |a (NLM)37517898 | ||
| 035 | |a (PII)S1078-1439(23)00238-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jacob, Joseph M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: UGN-101 has been approved for the chemoablation of low-grade upper tract urothelial cancer (UTUC) involving the renal pelvis and calyces. Herein is the first reported cohort of patients with ureteral tumors treated with UGN-101 | ||
| 520 | |a PATIENTS AND METHODS: We performed a retrospective review of patients treated with UGN-101 for UTUC at 15 high-volume academic and community centers focusing on outcomes of patients treated for ureteral disease. Patients received UGN-101 with either adjuvant or chemo-ablative intent. Response rates are reported for patients receiving chemo-ablative intent. Adverse outcomes were characterized with a focus on the rate of ureteral stenosis | ||
| 520 | |a RESULTS: In a cohort of 132 patients and 136 renal units, 47 cases had tumor involvement of the ureter, with 12 cases of ureteral tumor only (8.8%) and 35 cases of ureteral plus renal pelvic tumors (25.7%). Of the 23 patients with ureteral involvement who received UGN-101 induction with chemo-ablative intent, the complete response was 47.8%, which did not differ significantly from outcomes in patients without ureteral involvement. Fourteen patients (37.8%) with ureteral tumors had significant ureteral stenosis at first post-treatment evaluation, however, when excluding those with pre-existing hydronephrosis or ureteral stenosis, only 5.4% of patients developed new clinically significant stenosis | ||
| 520 | |a CONCLUSIONS: UGN-101 appears to be safe and may have similar efficacy in treating low-grade urothelial carcinoma of the ureter as compared to renal pelvic tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chemoablation | |
| 650 | 4 | |a Jelmyto | |
| 650 | 4 | |a UGN-101 | |
| 650 | 4 | |a UTUC | |
| 650 | 4 | |a Upper tract urothelial cancer | |
| 650 | 4 | |a Ureter | |
| 650 | 4 | |a Ureteral | |
| 650 | 4 | |a Ureteral cancer | |
| 650 | 7 | |a Mitomycins |2 NLM | |
| 700 | 1 | |a Woldu, Solomon L |e verfasserin |4 aut | |
| 700 | 1 | |a Linehan, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Labbate, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Rose, Kyle M |e verfasserin |4 aut | |
| 700 | 1 | |a Sexton, Wade J |e verfasserin |4 aut | |
| 700 | 1 | |a Tachibana, Isamu |e verfasserin |4 aut | |
| 700 | 1 | |a Kaimakliotis, Hristos |e verfasserin |4 aut | |
| 700 | 1 | |a Nieder, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Bjurlin, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Humphreys, Mitchell |e verfasserin |4 aut | |
| 700 | 1 | |a Ghodoussipour, Saum B |e verfasserin |4 aut | |
| 700 | 1 | |a Quek, Marcus L |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Eisner, Brian H |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Adam S |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Katie S |e verfasserin |4 aut | |
| 700 | 1 | |a Matin, Surena F |e verfasserin |4 aut | |
| 700 | 1 | |a Lotan, Yair |e verfasserin |4 aut | |
| 700 | 1 | |a Dickstein, Rian J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 42(2024), 1 vom: 01. Jan., Seite 20.e17-20.e23 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:20.e17-20.e23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2023.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 01 |c 01 |h 20.e17-20.e23 | ||